The development of innovative Multiplexed Molecular Imaging technology targeting improved diagnostic imaging of Glioblastoma Multiforme

开发创新的多重分子成像技术，旨在改善多形性胶质母细胞瘤的诊断成像

• 批准号: nhmrc : 1021759
• 负责人: A/Pr Paul Thomas
• 金额: $ 26.91万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-innovative-multiplexed-glioblastoma-multiforme/110146
• 关键词: development; innovative; Multiplexed; Molecular; Imaging

Glioblastoma Multiforme (GBM) is extremely invasive and the most lethal of all primary brain tumours. To optimise treatment planning, we propose to develop novel Multiplexed Molecular Imaging (MMI) technology employing the latest PET-MRI hybrid imaging technology. Our strategy targets the development of new F19 MRI MI agents for measuring tumour infiltration that can be multiplexed with F18 PET hypoxia tracers. Our MI agents can also act as conjugative vehicles for drug delivery.

多形性胶质母细胞瘤（GBM）是所有原发性脑肿瘤中侵袭性极强且最致命的。为了优化治疗计划，我们建议采用最新的PET-MRI混合成像技术开发新型的多重分子成像（MMI）技术。我们的战略目标是开发新的F19 MRI MI药物，用于测量肿瘤浸润，可与F18 PET缺氧示踪剂复合。我们的MI试剂还可以作为药物递送的接合载体。